The acquisition is to build global pharma business

PMC YM-Pharma Private Ltd has acquired the assets of Yegna Manojavam Drugs and Chemicals Ltd (YMDCL) of Hyderabad.

The cGMP manufacturing facility of YMDCL is one of the largest fluoroquinolone drug manufacturers in India and prides itself on its zero-discharge effluent management system.

With the additional focus designed to serve the needs of Oncology, Neuropsychiatry, Gastro-Intestinal, Pulmonary Hypertension, Anti-Depressant and Anti-Migraine pharmaceuticals, PMC YM-Pharma Private Ltd plans to become a major market player in providing cost effective generic drugs and drug intermediates to the global market.

“This acquisition begins our journey toward building a global pharmaceutical business,” said Dr. Raj Chakrabarti, Vice President and Chief Strategy Officer of PMC Group International.

The New Jersey-based PMC operates from a global manufacturing, innovation and marketing platform with facilities in the Americas, Europe and Asia.

It is a subsidiary of PMC Group International, an independent arm of PMC Group Inc. fii-news.com